The UVA Cancer Center seeks adults with primary cutaneous, mucosal, or unknown melanoma (stage IB ulcerated, II, III, or IV melanoma) or stage II, III, or IV uveal melanoma for a research study. The purpose of the study is to test the effectiveness of a melanoma vaccine made of peptides (short pieces of proteins found in melanoma and sometimes normal cells) called 6MHP and NeoAg-mBRAF, as well as adjuvants (which help your body make immune responses against the proteins) called CDX-1140 and polyICLC.
You may be eligible for this study if you have been determined to be free of disease in the last 6 months and if you have at least 6 skin moles.
The study involves getting a vaccine in one place in your body three times and in another place six times. The vaccines are usually given in an arm or a leg. The study also involves having your moles biopsied, having two biopsies where the vaccine is given, and having one biopsy of a lymph node. Blood will be drawn 10 times for study purposes. During the active treatment portion of the study, you will come in for up to 8 visits over 85 days (about 3 months). Each visit will last about 2 to 7 hours.
Study-related procedures, including but not limited to the biopsies and vaccine, will be provided at no cost.
For more information, please visit https://clinicaltrials.gov/ct2/show/NCT04364230